双鹭药业(002038) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥153,893,261.65, representing a year-on-year increase of 3.63%[5] - Net profit attributable to shareholders for Q3 2025 reached ¥20,049,842.08, a significant increase of 143.28% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,330,451.32, reflecting a decrease of 62.39% year-on-year[5] - Total operating revenue for the period was RMB 458,752,567.68, a decrease of 15.1% compared to RMB 540,562,431.05 in the previous period[17] - The company's operating profit for the current period is 162,030,693.89, compared to a loss of 32,315,344.24 in the previous period[18] - Net profit attributable to shareholders of the parent company is 141,098,044.78, a significant recovery from a loss of 16,735,581.13 in the previous period[19] - Basic and diluted earnings per share for the current period are both 0.1373, compared to -0.0163 in the previous period[19] Assets and Liabilities - The company's total assets at the end of Q3 2025 amounted to ¥6,028,688,138.33, an increase of 0.83% from the end of the previous year[5] - Current assets totaled RMB 2,586,400,343.39, an increase of 3.9% from RMB 2,488,838,965.65 at the beginning of the period[15] - Inventory increased significantly to RMB 394,807,069.61, up 60.2% from RMB 246,333,789.57[15] - Non-current assets totaled RMB 3,442,287,794.94, a decrease of 1.4% from RMB 3,490,180,353.09[15] - Total assets reached RMB 6,028,688,138.33, an increase from RMB 5,979,019,318.74 at the beginning of the period[16] - Total liabilities decreased to RMB 327,956,298.26, down 17.6% from RMB 398,371,079.36[16] - Shareholders' equity increased to RMB 5,700,731,840.07, up from RMB 5,580,648,239.38[16] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥5,831,738.30, a decline of 104.56% compared to the same period last year[5] - Total cash inflow from operating activities is 1,166,739,406.02, up from 647,132,663.44 in the previous period[22] - The net cash flow from operating activities is -5,831,738.30, a decline from a positive cash flow of 127,831,479.42 in the previous period[22] - Investment activities generated a net cash flow of -10,472,195.04, an improvement from -90,221,695.76 in the previous period[22] - The company reported a cash and cash equivalents balance of 363,027,327.07 at the end of the period, down from 423,550,721.97 at the end of the previous period[22] - Cash and cash equivalents decreased to RMB 383,945,973.08 from RMB 411,958,243.66, a decline of 6.8%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,779[10] - The largest shareholder, Xu Mingbo, holds 22.62% of the shares, totaling 232,406,307 shares[11] Expenses - The company incurred research and development expenses of 75,104,850.67, a decrease from 98,929,930.35 in the previous period[18] - Sales expenses decreased to 73,477,652.02 from 91,222,553.23 in the previous period[18] - The company experienced a tax expense of 18,229,121.33, compared to a tax benefit of -19,420,932.88 in the previous period[18] Fair Value Changes - The company recognized a fair value change gain of ¥1.28 billion in Q3 2025, a year-on-year increase of 204.93%[9] Business Operations - The company has expanded its product trade business, which has led to increased cash outflows for purchasing goods[9]